Background:

During puberty, mammary tissue undergoes rapid development, which provides a window of heightened susceptibility of breast composition to the influence of endogenous and exogenous hormones. Exposure to endocrine-disrupting chemicals (EDC) may affect breast development and composition and the risk of developing breast cancer in adulthood.

Methods:

We evaluated the associations between breast density and urinary concentrations of phenols and phthalates collected at Tanner 1 (B1) and Tanner 4 (B4) in 200 Chilean girls. Total breast volume (BV), fibroglandular volume (FGV), and percent dense breast (%FGV) were evaluated at B4 using dual X-ray absorptiometry. Generalized estimating equations were used to analyze the association between concentrations of EDC biomarkers across puberty and breast density.

Results:

The geometric mean %FGV was 7% higher among girls in the highest relative to the lowest tertile of monocarboxyisooctyl phthalate [1.07; 95% confidence interval (CI), 1.01–1.14]. Monoethyl phthalate concentrations at B4 were positively associated with FGV (highest vs. lowest tertile: 1.22; 95% CI, 1.06–1.40). Bisphenol A displayed a U-shaped association with FGV; girls in the middle tertile had at least 10% lower FGV than girls in the lowest or highest tertiles. Monocarboxyisononyl phthalate showed a nonlinear association with BV. No other statistically significant associations were observed.

Conclusions:

Our results suggest that the developing breast tissue is susceptible to select EDCs during childhood and adolescence.

Impact:

This study may spur further investigations into environmental influences on breast development during puberty and how shifts in pubertal breast density track through the life course to modify breast cancer risk.

High mammographic density is strongly associated with increased breast cancer risk (1–3). A greater proportion of dense breast tissue is indicative of relatively more collagen, epithelial, and stromal cells relative to fat (4). Increasing age, parity, and menopause are all associated with reductions in breast density, reflecting a shift in the relative abundance of these cell types (5). Greater body fatness during childhood and adolescence has been associated with decreased adult breast density (6, 7). Total breast volume (BV) of young women, estimated by cup size, has also been associated with breast cancer risk (8, 9). Results from these studies suggest that breast density is modifiable but largely dependent on initial peak density established during adolescence (10). Furthermore, it is during this period of rapid development and cell proliferation that the susceptibility of mammary tissue to carcinogens is suspected to be the greatest (11–13).

Pubertal breast development follows a coordinated surge in adrenal hormones preceding the reactivation of hypothalamic–pituitary–ovarian axis and production of estrogen from the ovaries (14). Accordingly, during this period of rapid hormone-sensitive development, mammary tissue may be particularly susceptible to endocrine-disrupting chemicals (EDC), which have the potential to interfere with the action of the body's endogenous hormones (15). Phenols and phthalates are two classes of pervasive EDCs found in plastics, personal care products, adhesives, detergents, pharmaceuticals, and building materials (16–18). Despite their ubiquity, there are surprisingly few investigations into the potential impact of these compounds on human breast development and subsequent cancer risk. One prior longitudinal study of girls from the United States reported no association between childhood phthalate biomarkers in urine and the age of breast development (thelarche; ref. 19). Within the same cohort, phenol urinary biomarkers demonstrated a more complicated relation with age at thelarche. Although benzophenone-3 was associated with earlier thelarche, 2,5-dichlorophenol and triclosan were associated with later development (20). Only one study has investigated the potential association between phthalate exposure and breast cancer risk. In a case–control study of Mexican women, urinary concentrations of monoethyl phthalate (MEP) were associated with increased odds of premenopausal breast cancer, whereas monobenzyl phthalate (MBzP) and mono(3-carboxypropyl) phthalate (MCPP) were associated with lower odds (21).

These prior studies suggest that pubertal breast development might be sensitive to EDC exposure. However, no studies have explored how breast composition responds to EDC exposure during childhood and adolescence. To address these gaps in knowledge, we investigated the association between childhood and adolescent EDC urinary biomarkers and pubertal breast density in a longitudinal cohort of girls in Santiago, Chile. This study provides unique insight into the potential influence of early life exposures on determinants of breast cancer risk.

Study population

Our study population was the longitudinal Growth and Obesity Cohort Study (GOCS) in Santiago, Chile. Initiated in 2006, children ages 2.6 to 4.0 years were recruited from public nursery schools of six counties in Santiago who met the following inclusion criteria: (1) singletons born in 2002–2003 and with birthweight between 2,500 and 4,500 g, and (2) absence of physical (e.g., skin burn), medical (e.g., brain tumor), or endocrine diseases (e.g., hyperthyroidism, hyperprolactinemia) that can alter the growth and/or onset of puberty. Of 1,498 eligible participants, 1,195 (∼80%) agreed to participate in the study. No significant differences in age, gender, and birth anthropometry were identified between the final participants and those not enrolled. The GOCS children are representative of the low- to middle-income families served by the public nursery schools. Two trained dietitians collected anthropometry measurements approximately every 6 months after 2006. Based on height (cm) and weight (kg) measured at each clinic visit, sex and age-adjusted body mass index (BMI) Z-scores were calculated using the Centers for Disease Control and Prevention (CDC) growth charts. Of the 515 girls who participated in the original cohort, 389 girls had follow-up information through B4 and consented to have breast density measured using dual X-ray absorptiometry. Due to the limits in available funds, the current study was restricted to a subset of 200 randomly sampled girls with urine samples collected at both Tanner 1 (B1) and Tanner 4 (B4), and with breast density measurements performed at B4. Among the 389 girls with breast density measurements, total BV, fibroglandular volume (FGV), and percent dense breast (%FGV) adjusting for BMI Z-score at B4 did not significantly differ between those included and excluded from the current analysis. The study protocol was conducted in accordance with the Declaration of Helsinki guidelines and was approved by the Ethics Committee of the Institute of Nutrition and Food Technology, University of Chile, and the Institutional Review Board of the Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Informed written consent was obtained from all parents or guardians of children before the start of data collection.

Breast density measurements

Breast density was measured at B4, when total FGV is assumed to reach its peak (22). Breast development was assessed by visual inspection using the Tanner rating scale approximately every 6 months (23). After confirming the absence of pregnancy by a urine test, DXA was used to measure dense tissue volume (absolute FGV) of the breast. The UCSF DXA breast scanning protocol was developed by Shepherd and colleagues, in the Department of Radiology and Biomedical Imaging, University of California, San Francisco (version 5; ref. 24). Each breast was scanned using the Prodigy DXA system software (version 13.6, series 200674; GE Healthcare). A quality control phantom containing reference breast density materials was scanned throughout the study to assure a stable calibration. This approach has been shown to have high validity and precision for measuring breast density in girls at different Tanner stages (22). The radiation dose from DXA is exceedingly small; DXA is commonly used to measure whole body percent fat and body mass in pediatric studies (25). Total projected breast area was manually delineated on each image and breast FGV (cm3) and total volume (BV; cm3) was estimated using a two-compartment model of adipose and fibroglandular tissue with software developed by Shepherd and colleagues at the University of California (26). Percent FGV (%FGV) was defined as the proportion FGV relative to BV times 100. We averaged the values of the left and right breast for all analyses.

EDC measurements

Fasting spot urine samples were collected between 10 AM and 12 PM in polypropylene sterile cups, immediately vortexed, aliquoted, and stored at −20°C until analysis. Previous evaluations indicate that the integrity of the specimens and stability of the biomarkers are not compromised under these conditions (27, 28). Concentrations of 26 phenols and phthalates biomarkers were quantified in urines collected at B1 and B4 from 200 girls (400 urine samples). Biomarker measurements were performed at the CDC using described analytical methods; each analytic batch includes reagent blanks and low- and high-concentration quality control materials, which are evaluated using standard statistical probability rules (29, 30). Concentrations below the limit of detection (LOD) were given an imputed value equal to LOD/sqrt(2). Dilution adjustment was performed using the formula Pc = P[(1.015–1)/(SG-1)], where Pc is the specific gravity-corrected biomarker concentration, P is the observed biomarker concentration, SG is the specific gravity of the urine sample, and 1.015 is the median SG of the study population (31, 32). The analysis of blinded specimens by the CDC laboratory was determined not to constitute engagement in human subjects' research.

Statistical analysis

Generalized estimating equations (GEE) were used to jointly estimate the influence of EDC biomarker concentrations at B1 and B4 on breast density measurements, including total BV, absolute FGV, and percent FGV. This nonconventional application of GEE models allows for the simultaneous modeling of the associations with B1 and B4 EDC biomarker concentrations, with a working independence assumption and model-based standard errors (33, 34). Breast density measurements were log-transformed prior to analysis. Time-varying associations between EDC biomarker concentrations and breast density were investigated by evaluating the significance of the interaction between biomarker concentrations and Tanner stage at biomarker measurement on breast density. Reported associations were stratified by Tanner stage if significant statistical interaction was detected (Wald test; P < 0.05). To account for potential nonlinear associations, we modeled tertiles of EDC biomarker concentrations, with tertile cut-points stratified by Tanner stage. Multivariate Wald tests were used to assess whether breast composition was significantly different between any tertile of EDC biomarker concentrations (“overall test”). Significant trends across categories were evaluated by modeling the log-transformed median biomarker concentration within tertiles as a continuous variable. All models were adjusted for age at B1 EDC biomarker measurement, age at B4 EDC biomarker measurement, BMI Z-score at B1, and BMI Z-score at B4. Models were additionally adjusted for maternal education as an indicator of socio-economic status, which has been related to both exposure profile and breast density (35–38). Associations between breast density measurements and biomarker concentrations were reported as the relative change in geometric mean and 95% confidence interval (CI) by exponentiating the associations with log-transformed breast density measurement. Least-square means were used to visualize the absolute change in breast density measurements between tertiles of EDC biomarker concentrations in adjusted GEE models. For significant (overall test, P < 0.05) nonmonotonic associations between EDC biomarker concentration and breast density, we additionally modeled urinary biomarker concentrations continuously, including a main effect and interaction with each of the other quantified biomarkers (dichotomized by mean). For models significantly improved by the inclusion of another EDC biomarker and the relevant interaction term (multivariate Wald test, P < 0.01), we reported the stratum-specific associations. All statistical analyses were performed in R Version 3.3.1, and figures were generated using ggplot2 (39).

Urinary concentrations of 26 phenol and phthalate biomarkers were quantified in 200 Chilean adolescent girls at breast Tanner stages B1 and B4 as previously described (40). Data analysis was restricted to the subset of 21 biomarkers that were detected in at least 75% of the girls at both time points. In this subset of the ongoing GOCS, urine samples were obtained during B1 between the ages of 6.7 and 9.6 years, with a median collection age of 7.9 years. Urine B4 samples were collected between the ages of 9.4 and 13.1 years, with a median age of 11.2 years (40). The time between EDC biomarker measurements in this cohort ranged from 2 to 5 years. Correlations between B1 and B4 EDC biomarker concentrations in these girls were moderate to weak, reflecting changes in exposure profiles over time (40). On average, biomarker concentrations at B4 were slightly lower than at B1, paralleling a similar trend observed among adolescent U.S. girls of the same age participating in the National Health and Nutrition Examination Survey (40). Furthermore, the correlation between individual biomarkers varied by Tanner stage (Supplementary Figs. S1 and S2). Approximately 90% of the girls reached menarche after the first visit establishing B4 (n = 179). No EDC biomarker, measured at Tanner 1 or Tanner 4, was significantly (P < 0.05) associated with the occurrence of menarche prior to the first observed visit of B4. The median BMI Z-score at B1 urine collection was −0.1 (range, −2.6, 2.1) and 0.1 (range, –2.1, 2.3) at breast density measurement. Approximately 23% of the mothers had postsecondary education (40).

Total BV

Monocarboxyisononyl phthalate (MCNP) was the only biomarker significantly associated with total BV, adjusting for age and BMI Z-score at biomarker measurement, as well as maternal education (overall test, P < 0.05; Table 1). Although BV among girls in the middle tertile was not significantly different from those in the lowest, volume was 10% greater in the highest tertile compared with the middle tertile (1.10; 95% CI, 1.02–1.18; Table 1 and Fig. 1A). We hypothesized that this nonmonotonic U-shaped association may indicate an interaction between MCNP and another EDC on BV. Therefore, we analyzed the influence of adding a main effect and interaction with each of the other biomarkers. Adding dichotomized (relative to the median) MEP concentrations and an interaction with continuous MCNP concentrations significantly improved model fit (P < 0.01, multivariate Wald tests; Supplementary Table S1). Among girls with high MEP concentrations, a one log (ng/mL) increase in MCNP was associated with a 6% increase in BV (1.06; 95% CI, 1.01–1.10). We additionally detected a significant trend across tertiles of 2,4-dichlorophenol concentrations; girls in the highest tertile had 9% lower geometric mean BV than girls in the lowest tertile (0.91; 95% CI, 0.84–0.99). However, the overall test of whether BV significantly varied between categories of 2,4-dichlorophenol concentrations was not significant.

Table 1.

Relative shift in geometric mean (95% CI) BV between tertiles of each phenol and phthalate biomarker across B1 and B4a

EDCOverall testb (P value)Middle vs. lowest tertile (ref.)Highest vs. lowest tertile (ref.)Highest vs. middle tertile (ref.)Trendc (P value)
2,4-Dichlorophenol 0.108 0.97 (0.89–1.05) 0.91* (0.84–0.99) 0.94 (0.86–1.03) 0.032* 
2,5-Dichlorophenol 0.198 1.02 (0.93–1.11) 1.07 (0.99–1.16) 1.05 (0.97–1.13) 0.057 
Benzophenone-3 0.695 1.03 (0.95–1.11) 1.03 (0.96–1.12) 1.01 (0.94–1.09) 0.380 
BPA 0.356 0.95 (0.88–1.02) 0.96 (0.88–1.05) 1.02 (0.94–1.11) 0.448 
Methyl paraben 0.679 0.97 (0.89–1.05) 0.99 (0.91–1.08) 1.03 (0.95–1.11) 0.804 
MBP 0.329 0.95 (0.88–1.02) 0.97 (0.90–1.04) 1.02 (0.95–1.10) 0.453 
MBzP 0.184 0.93 (0.87–1.01) 0.95 (0.87–1.04) 1.02 (0.94–1.10) 0.243 
MCNP 0.043* 0.94 (0.86–1.02) 1.03 (0.96–1.10) 1.10* (1.02–1.18) 0.369 
MCOP 0.852 1.03 (0.94–1.12) 1.02 (0.94–1.10) 0.99 (0.91–1.08) 0.706 
MCPP 0.708 0.97 (0.90–1.06) 1.01 (0.94–1.09) 1.04 (0.95–1.13) 0.766 
MECPP 0.735 0.97 (0.89–1.05) 1.00 (0.92–1.08) 1.03 (0.94–1.13) 0.936 
MEHHP 0.919 0.99 (0.91–1.08) 1.01 (0.93–1.09) 1.02 (0.93–1.11) 0.741 
MEHP 0.077 0.92* (0.85–1.00) 0.93 (0.86–1.01) 1.01 (0.93–1.11) 0.108 
MEOHP 0.908 0.98 (0.91–1.07) 0.99 (0.92–1.07) 1.01 (0.93–1.09) 0.855 
MEP 0.600 1.02 (0.94–1.12) 1.04 (0.96–1.14) 1.02 (0.94–1.11) 0.296 
MHBP 0.767 0.97 (0.90–1.05) 1.00 (0.92–1.07) 1.02 (0.95–1.10) 0.902 
MHiBP 0.915 0.99 (0.91–1.06) 1.00 (0.91–1.09) 1.01 (0.94–1.09) 0.949 
MiBP 0.517 1.04 (0.96–1.12) 1.00 (0.91–1.09) 0.96 (0.89–1.04) 0.967 
MMP 0.544 0.97 (0.90–1.05) 1.02 (0.94–1.10) 1.05 (0.96–1.13) 0.716 
Propyl paraben 0.811 1.02 (0.94–1.11) 1.02 (0.94–1.11) 1.00 (0.92–1.08) 0.582 
Triclosan 0.226 0.96 (0.89–1.04) 0.93 (0.85–1.01) 0.96 (0.89–1.04) 0.070 
EDCOverall testb (P value)Middle vs. lowest tertile (ref.)Highest vs. lowest tertile (ref.)Highest vs. middle tertile (ref.)Trendc (P value)
2,4-Dichlorophenol 0.108 0.97 (0.89–1.05) 0.91* (0.84–0.99) 0.94 (0.86–1.03) 0.032* 
2,5-Dichlorophenol 0.198 1.02 (0.93–1.11) 1.07 (0.99–1.16) 1.05 (0.97–1.13) 0.057 
Benzophenone-3 0.695 1.03 (0.95–1.11) 1.03 (0.96–1.12) 1.01 (0.94–1.09) 0.380 
BPA 0.356 0.95 (0.88–1.02) 0.96 (0.88–1.05) 1.02 (0.94–1.11) 0.448 
Methyl paraben 0.679 0.97 (0.89–1.05) 0.99 (0.91–1.08) 1.03 (0.95–1.11) 0.804 
MBP 0.329 0.95 (0.88–1.02) 0.97 (0.90–1.04) 1.02 (0.95–1.10) 0.453 
MBzP 0.184 0.93 (0.87–1.01) 0.95 (0.87–1.04) 1.02 (0.94–1.10) 0.243 
MCNP 0.043* 0.94 (0.86–1.02) 1.03 (0.96–1.10) 1.10* (1.02–1.18) 0.369 
MCOP 0.852 1.03 (0.94–1.12) 1.02 (0.94–1.10) 0.99 (0.91–1.08) 0.706 
MCPP 0.708 0.97 (0.90–1.06) 1.01 (0.94–1.09) 1.04 (0.95–1.13) 0.766 
MECPP 0.735 0.97 (0.89–1.05) 1.00 (0.92–1.08) 1.03 (0.94–1.13) 0.936 
MEHHP 0.919 0.99 (0.91–1.08) 1.01 (0.93–1.09) 1.02 (0.93–1.11) 0.741 
MEHP 0.077 0.92* (0.85–1.00) 0.93 (0.86–1.01) 1.01 (0.93–1.11) 0.108 
MEOHP 0.908 0.98 (0.91–1.07) 0.99 (0.92–1.07) 1.01 (0.93–1.09) 0.855 
MEP 0.600 1.02 (0.94–1.12) 1.04 (0.96–1.14) 1.02 (0.94–1.11) 0.296 
MHBP 0.767 0.97 (0.90–1.05) 1.00 (0.92–1.07) 1.02 (0.95–1.10) 0.902 
MHiBP 0.915 0.99 (0.91–1.06) 1.00 (0.91–1.09) 1.01 (0.94–1.09) 0.949 
MiBP 0.517 1.04 (0.96–1.12) 1.00 (0.91–1.09) 0.96 (0.89–1.04) 0.967 
MMP 0.544 0.97 (0.90–1.05) 1.02 (0.94–1.10) 1.05 (0.96–1.13) 0.716 
Propyl paraben 0.811 1.02 (0.94–1.11) 1.02 (0.94–1.11) 1.00 (0.92–1.08) 0.582 
Triclosan 0.226 0.96 (0.89–1.04) 0.93 (0.85–1.01) 0.96 (0.89–1.04) 0.070 

aEstimating average association across B1 and B4 EDC measurements using a multivariable GEE model adjusting for age at B1 EDC measurement, age at B4 EDC measurement, BMI z-score at B1, BMI z-score at B4, and maternal education.

bOverall test whether EDC category improves model fit (multivariate Wald test).

cTrend evaluated by modeling the log(median) concentration within tertiles as a continuous variable.

*P < 0.05.

Figure 1.

Changes in breast density associated with urinary phenol and phthalate biomarker concentrations. T1 = lowest tertile, T2 = middle tertile, and T3 = highest tertile. Plotting the least-square means and associated 95% CI of (A) BV, (B) FGV, and (C) %FGV between tertiles of biomarker concentrations based on GEE models adjusting for age at B1 biomarker measurement, age at B4 biomarker measurement, BMI z-score at B1, BMI z-score at B4, and maternal education. Significant difference (P < 0.05) between tertiles T1 and T2 indicated by A, tertiles T2 and T3 indicated by B, and tertiles T1 and T3 indicated by C.

Figure 1.

Changes in breast density associated with urinary phenol and phthalate biomarker concentrations. T1 = lowest tertile, T2 = middle tertile, and T3 = highest tertile. Plotting the least-square means and associated 95% CI of (A) BV, (B) FGV, and (C) %FGV between tertiles of biomarker concentrations based on GEE models adjusting for age at B1 biomarker measurement, age at B4 biomarker measurement, BMI z-score at B1, BMI z-score at B4, and maternal education. Significant difference (P < 0.05) between tertiles T1 and T2 indicated by A, tertiles T2 and T3 indicated by B, and tertiles T1 and T3 indicated by C.

Close modal

FGV

A few distinct biomarkers were associated with dense breast volume (FGV), including MEP, mono-isobutyl phthalate (MiBP), and bisphenol A (BPA; Tables 2 and 3; Fig. 1B). For MEP and MiBP, the association with FGV was modified by the time of biomarker measurement (Table 3). Concentrations of MEP were moderately correlated between the two Tanner stages (Spearman ρ = 0.325; ref. 40). However, MEP-specific gravity-adjusted geometric mean concentration was nearly 20 ng/mL higher at B1 than B4 (40). Concentrations of MiBP did not significantly differ between Tanner stages, and were moderately correlated between B1 and B4 (Spearman ρ = 0.279; ref. 40). After stratifying by Tanner stage at biomarker measurement, tertiles of MiBP concentration were not significantly associated with FGV (overall test; Table 3). Distinctly, B4 MEP concentrations had a positive association with FGV (trend test, P = 0.004). Girls with MEP concentrations in the highest tertile at B4 had a 22% higher geometric mean volume than girls with MEP levels in the first tertile (1.22; 95% CI, 1.06–1.40). In contrast, BPA had a clear nonlinear association with dense volume across Tanner stages. Girls in the middle tertile of BPA concentrations had at least 10% lower FGV than girls in either the lowest or highest tertiles (Table 2). BPA significantly interacted with MEP to influence dense volume, potentially contributing to this nonmonotonic association (P < 0.01, multivariate Wald tests for added biomarker and interaction; Supplementary Table S1). BPA was only significantly associated with FGV among girls with relatively low concentrations of MEP. A one log (ng/mL) increase in BPA was associated with a 7% decrease in geometric mean FGV among those with low concentrations of MEP (0.93; 95% CI, 0.87–1.00).

Table 2.

Relative shift in geometric mean (95% CI) FGV between tertiles of each phenol and phthalate biomarker across B1 and B4a

EDCOverall testb (P value)Middle vs. lowest tertile (ref.)Highest vs. lowest tertile (ref.)Highest vs. middle tertile (ref.)Trendc (P value)
2,4-Dichlorophenol 0.269 0.93 (0.84–1.03) 0.92 (0.82–1.03) 0.98 (0.88–1.10) 0.152 
2,5-Dichlorophenol 0.578 1.05 (0.95–1.17) 1.05 (0.94–1.17) 1.00 (0.91–1.10) 0.382 
Benzophenone-3 0.811 1.00 (0.91–1.11) 1.03 (0.93–1.14) 1.03 (0.93–1.13) 0.433 
BPA 0.008** 0.88** (0.80–0.97) 1.01 (0.90–1.12) 1.14* (1.03–1.26) 0.879 
Methyl paraben 0.824 0.99 (0.88–1.10) 1.01 (0.92–1.12) 1.03 (0.94–1.13) 0.876 
MBP 0.169 0.92 (0.84–1.00) 0.96 (0.87–1.06) 1.05 (0.96–1.15) 0.497 
MBzP 0.582 0.95 (0.86–1.05) 0.99 (0.88–1.10) 1.04 (0.94–1.14) 0.763 
MCNP 0.080 0.97 (0.88–1.08) 1.07 (0.97–1.18) 1.10* (1.01–1.20) 0.120 
MCOP 0.189 1.04 (0.93–1.16) 1.09 (0.99–1.21) 1.05 (0.95–1.16) 0.073 
MCPP 0.854 1.02 (0.92–1.13) 1.03 (0.93–1.13) 1.00 (0.90–1.12) 0.616 
MECPP 0.719 1.01 (0.91–1.12) 1.05 (0.94–1.16) 1.04 (0.92–1.16) 0.374 
MEHHP 0.708 0.99 (0.89–1.11) 1.04 (0.93–1.15) 1.04 (0.94–1.16) 0.489 
MEHP 0.237 0.91 (0.82–1.01) 0.98 (0.88–1.08) 1.07 (0.95–1.20) 0.715 
MEOHP 0.554 0.98 (0.88–1.08) 1.03 (0.93–1.15) 1.06 (0.96–1.17) 0.549 
MEP 0.194 1.03 (0.93–1.14) 1.09 (0.99–1.21) 1.06 (0.96–1.17) 0.065 
MHBP 0.687 0.97 (0.88–1.08) 1.01 (0.92–1.11) 1.04 (0.95–1.14) 0.772 
MHiBP 0.588 0.99 (0.89–1.10) 1.04 (0.93–1.16) 1.05 (0.96–1.15) 0.516 
MiBP 0.802 1.03 (0.93–1.14) 1.03 (0.93–1.15) 1.00 (0.91–1.10) 0.489 
MMP 0.252 1.02 (0.93–1.12) 1.08 (0.98–1.20) 1.06 (0.96–1.17) 0.116 
Propyl paraben 0.812 1.01 (0.91–1.12) 1.03 (0.94–1.14) 1.02 (0.93–1.12) 0.468 
Triclosan 0.130 0.91* (0.83–1.00) 0.93 (0.83–1.04) 1.02 (0.92–1.13) 0.218 
EDCOverall testb (P value)Middle vs. lowest tertile (ref.)Highest vs. lowest tertile (ref.)Highest vs. middle tertile (ref.)Trendc (P value)
2,4-Dichlorophenol 0.269 0.93 (0.84–1.03) 0.92 (0.82–1.03) 0.98 (0.88–1.10) 0.152 
2,5-Dichlorophenol 0.578 1.05 (0.95–1.17) 1.05 (0.94–1.17) 1.00 (0.91–1.10) 0.382 
Benzophenone-3 0.811 1.00 (0.91–1.11) 1.03 (0.93–1.14) 1.03 (0.93–1.13) 0.433 
BPA 0.008** 0.88** (0.80–0.97) 1.01 (0.90–1.12) 1.14* (1.03–1.26) 0.879 
Methyl paraben 0.824 0.99 (0.88–1.10) 1.01 (0.92–1.12) 1.03 (0.94–1.13) 0.876 
MBP 0.169 0.92 (0.84–1.00) 0.96 (0.87–1.06) 1.05 (0.96–1.15) 0.497 
MBzP 0.582 0.95 (0.86–1.05) 0.99 (0.88–1.10) 1.04 (0.94–1.14) 0.763 
MCNP 0.080 0.97 (0.88–1.08) 1.07 (0.97–1.18) 1.10* (1.01–1.20) 0.120 
MCOP 0.189 1.04 (0.93–1.16) 1.09 (0.99–1.21) 1.05 (0.95–1.16) 0.073 
MCPP 0.854 1.02 (0.92–1.13) 1.03 (0.93–1.13) 1.00 (0.90–1.12) 0.616 
MECPP 0.719 1.01 (0.91–1.12) 1.05 (0.94–1.16) 1.04 (0.92–1.16) 0.374 
MEHHP 0.708 0.99 (0.89–1.11) 1.04 (0.93–1.15) 1.04 (0.94–1.16) 0.489 
MEHP 0.237 0.91 (0.82–1.01) 0.98 (0.88–1.08) 1.07 (0.95–1.20) 0.715 
MEOHP 0.554 0.98 (0.88–1.08) 1.03 (0.93–1.15) 1.06 (0.96–1.17) 0.549 
MEP 0.194 1.03 (0.93–1.14) 1.09 (0.99–1.21) 1.06 (0.96–1.17) 0.065 
MHBP 0.687 0.97 (0.88–1.08) 1.01 (0.92–1.11) 1.04 (0.95–1.14) 0.772 
MHiBP 0.588 0.99 (0.89–1.10) 1.04 (0.93–1.16) 1.05 (0.96–1.15) 0.516 
MiBP 0.802 1.03 (0.93–1.14) 1.03 (0.93–1.15) 1.00 (0.91–1.10) 0.489 
MMP 0.252 1.02 (0.93–1.12) 1.08 (0.98–1.20) 1.06 (0.96–1.17) 0.116 
Propyl paraben 0.812 1.01 (0.91–1.12) 1.03 (0.94–1.14) 1.02 (0.93–1.12) 0.468 
Triclosan 0.130 0.91* (0.83–1.00) 0.93 (0.83–1.04) 1.02 (0.92–1.13) 0.218 

aEstimating average association across B1 and B4 EDC measurements using a multivariable GEE model adjusting for age at B1 EDC measurement, age at B4 EDC measurement, BMI z-score at B1, BMI z-score at B4, and maternal education.

bOverall test whether EDC category improves model fit (multivariate Wald test).

cTrend evaluated by modeling the log(median) concentration within tertiles as a continuous variable.

*P < 0.05.

**P < 0.01.

Table 3.

Relative shift in geometric mean (95% CI) FGV between tertiles of MEP and MiBP concentrations stratified by Tanner stage at EDC measurementa

EDCTanner stageOverall testb (P value)Middle vs. lowest tertile (ref.)Highest vs. lowest tertile (ref.)Highest vs. middle tertile (ref.)Trendc (P value)
MEP 
 B1 0.590 1.06 (0.92–1.22) 0.99 (0.85–1.14) 0.93 (0.81–1.07) 0.752 
 B4 0.006** 1.00 (0.88–1.15) 1.22** (1.06–1.40) 1.21** (1.06–1.39) 0.004** 
MiBP 
 B1 0.214 0.90 (0.78–1.04) 1.01 (0.87–1.16) 1.12 (0.97–1.29) 0.942 
 B4 0.075 1.17* (1.02–1.35) 1.06 (0.92–1.22) 0.90 (0.79–1.04) 0.377 
EDCTanner stageOverall testb (P value)Middle vs. lowest tertile (ref.)Highest vs. lowest tertile (ref.)Highest vs. middle tertile (ref.)Trendc (P value)
MEP 
 B1 0.590 1.06 (0.92–1.22) 0.99 (0.85–1.14) 0.93 (0.81–1.07) 0.752 
 B4 0.006** 1.00 (0.88–1.15) 1.22** (1.06–1.40) 1.21** (1.06–1.39) 0.004** 
MiBP 
 B1 0.214 0.90 (0.78–1.04) 1.01 (0.87–1.16) 1.12 (0.97–1.29) 0.942 
 B4 0.075 1.17* (1.02–1.35) 1.06 (0.92–1.22) 0.90 (0.79–1.04) 0.377 

aEstimating Tanner stage–specific association between EDC metabolite and FGV using a multivariable GEE model adjusting for age at B1 EDC measurement, age at B4 EDC measurement, BMI z-score at B1, BMI z-score at B4, and maternal education, including an interaction between EDC tertile and Tanner stage, restricted to the subset of associations for which the interaction with Tanner stage was significant (P < 0.05).

bOverall test whether EDC category improves model fit (Likelihood ratio test).

cTrend evaluated by modeling the log(median) concentration within tertiles as a continuous variable.

*P < 0.05.

**P < 0.01.

%FGV

Although MCNP was only significantly associated with BV, we observed a similarly shaped trend with dense volume. Conversely, MEP and BPA were only associated with FGV. Considering this discordance, we would expect MEP and BPA to be associated with %FGV. In both cases, the association with %FGV was similar to the association with dense volume (Tables 4 and 5; Fig. 1C). An increase in B4 concentrations of MEP was associated with greater %FGV (Table 5). Paralleling the FGV association, girls with concentrations of BPA in the middle tertile had significantly lower %FGV than girls in the highest or lowest tertiles (Table 4). Percent FGV also had a significant positive relationship with monocarboxyisooctyl phthalate (MCOP; Table 4). Compared with girls in the first tertile, those in the highest tertile of MCOP concentrations had 7% higher %FGV (1.07; 95% CI, 1.01–1.14). Although the associations between this biomarker and FGV were not significant, the association trended in the same direction as with %FGV. The association between MCOP and %FGV was significantly modified by the occurrence of menarche prior to breast density measurement (Yes/No; Supplementary Table S2). The analysis restricted to girls that attained menarche after breast density measurement trended in a similar direction. However, the overall test of whether %FGV varied between MCOP tertiles was no longer significant. Monomethyl phthalate (MMP) similarly demonstrated a positive association with %FGV (trend P = 0.032). However, the overall test that tertiles of MMP concentration improved model fit for %FGV did not reach significance.

Table 4.

Relative shift in geometric mean (95% CI) %FGV between tertiles of each phenol and phthalate biomarker across B1 and B4a

EDCOverall testb (P value)Middle vs. lowest tertile (ref.)Highest vs. lowest tertile (ref.)Highest vs. middle tertile (ref.)Trendc (P value)
2,4-Dichlorophenol 0.369 0.96 (0.90–1.03) 1.00 (0.94–1.07) 1.04 (0.98–1.10) 0.872 
2,5-Dichlorophenol 0.221 1.03 (0.97–1.10) 0.98 (0.92–1.05) 0.95 (0.89–1.01) 0.410 
Benzophenone-3 0.707 0.98 (0.92–1.04) 1.00 (0.94–1.07) 1.02 (0.96–1.08) 0.779 
BPA 0.003** 0.93* (0.88–1.00) 1.04 (0.98–1.11) 1.12*** (1.05–1.19) 0.210 
Methyl paraben 0.802 1.02 (0.95–1.09) 1.02 (0.96–1.09) 1.00 (0.95–1.05) 0.635 
MBP 0.422 0.96 (0.91–1.02) 1.00 (0.93–1.06) 1.03 (0.97–1.10) 0.848 
MBzP 0.612 1.02 (0.95–1.09) 1.04 (0.97–1.11) 1.02 (0.96–1.08) 0.363 
MCNP 0.408 1.04 (0.97–1.11) 1.04 (0.98–1.11) 1.00 (0.95–1.06) 0.203 
MCOP 0.039* 1.01 (0.95–1.07) 1.07* (1.01–1.14) 1.06* (1.00–1.12) 0.022* 
MCPP 0.354 1.05 (0.98–1.12) 1.02 (0.96–1.08) 0.97 (0.91–1.03) 0.664 
MECPP 0.305 1.04 (0.98–1.10) 1.05 (0.98–1.12) 1.00 (0.94–1.07) 0.195 
MEHHP 0.726 1.00 (0.94–1.06) 1.02 (0.96–1.09) 1.02 (0.96–1.09) 0.486 
MEHP 0.265 1.00 (0.93–1.07) 1.04 (0.98–1.12) 1.05 (0.98–1.12) 0.168 
MEOHP 0.343 0.99 (0.93–1.05) 1.04 (0.97–1.11) 1.05 (0.98–1.12) 0.229 
MEP 0.352 1.01 (0.94–1.08) 1.05 (0.98–1.12) 1.04 (0.98–1.11) 0.172 
MHBP 0.787 1.00 (0.94–1.07) 1.02 (0.96–1.09) 1.02 (0.96–1.08) 0.566 
MHiBP 0.412 1.00 (0.94–1.07) 1.04 (0.97–1.12) 1.04 (0.98–1.10) 0.264 
MiBP 0.432 0.99 (0.93–1.07) 1.03 (0.97–1.10) 1.04 (0.98–1.11) 0.336 
MMP 0.083 1.05 (0.99–1.11) 1.07* (1.01–1.13) 1.02 (0.96–1.08) 0.032* 
Propyl paraben 0.785 0.98 (0.92–1.05) 1.00 (0.95–1.07) 1.02 (0.96–1.08) 0.727 
Triclosan 0.125 0.95 (0.89–1.01) 1.00 (0.94–1.07) 1.05 (0.99–1.12) 0.853 
EDCOverall testb (P value)Middle vs. lowest tertile (ref.)Highest vs. lowest tertile (ref.)Highest vs. middle tertile (ref.)Trendc (P value)
2,4-Dichlorophenol 0.369 0.96 (0.90–1.03) 1.00 (0.94–1.07) 1.04 (0.98–1.10) 0.872 
2,5-Dichlorophenol 0.221 1.03 (0.97–1.10) 0.98 (0.92–1.05) 0.95 (0.89–1.01) 0.410 
Benzophenone-3 0.707 0.98 (0.92–1.04) 1.00 (0.94–1.07) 1.02 (0.96–1.08) 0.779 
BPA 0.003** 0.93* (0.88–1.00) 1.04 (0.98–1.11) 1.12*** (1.05–1.19) 0.210 
Methyl paraben 0.802 1.02 (0.95–1.09) 1.02 (0.96–1.09) 1.00 (0.95–1.05) 0.635 
MBP 0.422 0.96 (0.91–1.02) 1.00 (0.93–1.06) 1.03 (0.97–1.10) 0.848 
MBzP 0.612 1.02 (0.95–1.09) 1.04 (0.97–1.11) 1.02 (0.96–1.08) 0.363 
MCNP 0.408 1.04 (0.97–1.11) 1.04 (0.98–1.11) 1.00 (0.95–1.06) 0.203 
MCOP 0.039* 1.01 (0.95–1.07) 1.07* (1.01–1.14) 1.06* (1.00–1.12) 0.022* 
MCPP 0.354 1.05 (0.98–1.12) 1.02 (0.96–1.08) 0.97 (0.91–1.03) 0.664 
MECPP 0.305 1.04 (0.98–1.10) 1.05 (0.98–1.12) 1.00 (0.94–1.07) 0.195 
MEHHP 0.726 1.00 (0.94–1.06) 1.02 (0.96–1.09) 1.02 (0.96–1.09) 0.486 
MEHP 0.265 1.00 (0.93–1.07) 1.04 (0.98–1.12) 1.05 (0.98–1.12) 0.168 
MEOHP 0.343 0.99 (0.93–1.05) 1.04 (0.97–1.11) 1.05 (0.98–1.12) 0.229 
MEP 0.352 1.01 (0.94–1.08) 1.05 (0.98–1.12) 1.04 (0.98–1.11) 0.172 
MHBP 0.787 1.00 (0.94–1.07) 1.02 (0.96–1.09) 1.02 (0.96–1.08) 0.566 
MHiBP 0.412 1.00 (0.94–1.07) 1.04 (0.97–1.12) 1.04 (0.98–1.10) 0.264 
MiBP 0.432 0.99 (0.93–1.07) 1.03 (0.97–1.10) 1.04 (0.98–1.11) 0.336 
MMP 0.083 1.05 (0.99–1.11) 1.07* (1.01–1.13) 1.02 (0.96–1.08) 0.032* 
Propyl paraben 0.785 0.98 (0.92–1.05) 1.00 (0.95–1.07) 1.02 (0.96–1.08) 0.727 
Triclosan 0.125 0.95 (0.89–1.01) 1.00 (0.94–1.07) 1.05 (0.99–1.12) 0.853 

aEstimating average association across B1 and B4 EDC measurements using a multivariable GEE model adjusting for age at B1 EDC measurement, age at B4 EDC measurement, BMI z-score at B1, BMI z-score at B4, and maternal education.

bOverall test whether EDC category improves model fit (multivariate Wald test).

cTrend evaluated by modeling the log(median) concentration within tertiles as a continuous variable.

*P < 0.05.

**P < 0.01.

***P < 0.001.

Table 5.

Relative shift in geometric mean (95% CI) %FGV between tertiles of MEP concentrations stratified by Tanner stage at EDC measurementa

EDCTanner stageOverall testb (P value)Middle vs. lowest tertile (ref.)Highest vs. lowest tertile (ref.)Highest vs. middle tertile (ref.)Trendc (P value)
MEP 
 B1 0.742 1.03 (0.94–1.12) 1.00 (0.91–1.09) 0.97 (0.89–1.06) 0.875 
 B4 0.026* 0.99 (0.91–1.07) 1.10* (1.01–1.20) 1.12* (1.02–1.22) 0.024* 
EDCTanner stageOverall testb (P value)Middle vs. lowest tertile (ref.)Highest vs. lowest tertile (ref.)Highest vs. middle tertile (ref.)Trendc (P value)
MEP 
 B1 0.742 1.03 (0.94–1.12) 1.00 (0.91–1.09) 0.97 (0.89–1.06) 0.875 
 B4 0.026* 0.99 (0.91–1.07) 1.10* (1.01–1.20) 1.12* (1.02–1.22) 0.024* 

aEstimating Tanner stage–specific association between EDC metabolite and %FGV using a multivariable GEE model adjusting for age at B1 EDC measurement, age at B4 EDC measurement, BMI z-score at B1, BMI z-score at B4, and maternal education, including an interaction between EDC tertile and Tanner stage, restricted to the subset of associations for which the interaction with Tanner stage was significant (P < 0.05).

bOverall test whether EDC category improves model fit (likelihood ratio test).

cTrend evaluated by modeling the log(median) concentration within tertiles as a continuous variable.

*P < 0.05.

This is the first investigation of the impact of childhood and adolescent exposure to phenols and phthalates on pubertal breast density. Although the correlations between the EDC biomarkers measured at B1 and B4 were low, the associations between these biomarkers and breast density were relatively consistent over time. The only two exceptions were the diethyl phthalate (DEP) metabolite, MEP, and the diisobutyl phthalate biomarker, MiBP. Only B4 biomarker concentrations of MEP were significantly associated with FGV. We speculate that the mechanism of action of MEP may depend on a threshold level of specific endogenous hormones, such as estradiol. In vitro, DEP causes significant proliferation of human breast cancer cell lines through activation of estrogen-receptor alpha (41, 42). Based on recombinant yeast screen assays, DEP has been shown to have weak estrogenic potential (43).

A few biomarkers demonstrated a nonlinear association with BV and density, including BPA and MCNP. Nonmonotonic dose–response relationships are relatively commonplace among in vitro and in vivo experimental studies of the health effects of EDC exposure (44). There are a number of mechanisms that may contribute to these phenomena, including multiple target receptors with different binding affinities and opposing action, stimulating negative feedback, and receptor desensitization. In the case of BPA and MCNP, these nonmonotonic associations reflected a significant interaction with another biomarker on breast composition, notably MEP. MCNP was only positively associated with BV among girls with high concentrations of MEP relative to the median. The relationship between FGV and BPA was inverted among girls with low concentrations of MEP. Concentrations of BPA and MEP, and MCOP and MEP were not correlated in this population, suggesting disparate routes of exposure. A common source of DEP, the parent compound of MEP, is personal care product use (45, 46). Given this unique exposure route, the observed statistical interactions with MEP may reflect unmeasured confounding by an element of hygiene routine. To address this question, future studies could be useful to disentangle specific routes of EDC exposure for Latina girls, which may greatly vary from U.S. or European populations.

Prior studies have suggested that childhood and adolescent levels of exogenous and endogenous sex hormones are associated with breast density. Compared with women who started hormonal contraceptives at older ages (22–28 years), initiation of hormonal contraceptive use between the ages of 12 and 17 years has been associated with higher young adult breast density (47). Prior to menarche, higher serum levels of dehydroepiandrosterone sulfate and sex hormone–binding globulin have also been positively associated with young adult breast density (48). This earlier study did not report a significant association with adolescent levels of estrogens, progesterone, androstenedione, or testosterone before or after menarche (48). Currently, little is known about how EDCs may interact with endogenous hormone levels in adolescent girls. One small study of 84 girls in Copenhagen found mono-n-butyl phthalate (MBP) was inversely associated (albeit not significantly) with adrenal androgens at age 13 (49). In our study, MBP was not significantly associated with breast density measurements. Research to assess whether endogenous hormone levels may interact with both phenol and phthalate biomarkers during puberty would increase our understanding of the potential implications for breast development.

Only one prior cross-sectional study has examined the association between EDC biomarker concentrations and breast density (50). This earlier study found a positive association between serum BPA and MEP and %FGV among approximately 250 postmenopausal women. A major criticism of this prior study was the use of serum biomarkers, which are more sensitive to contamination (51). However, these influences were likely to result in nondifferential measurement error and were postulated to bias associations toward the null. Urinary concentrations of MEP were associated with increased odds of breast cancer among Mexican women (21). Mirroring these findings, we report a positive association between B4 MEP urinary concentrations and adolescent breast density. In contrast, BPA had a nonmonotonic association with breast density in our study, possibly reflecting an interaction with MEP concentrations. Both of the prior investigations were restricted to a subset of the phenols and phthalates biomarkers evaluated in this study. Therefore, it is possible that some of the additional associations observed in the present study would have been observed at other ages. Alternatively, breast tissue may have specific windows of susceptibility to certain EDCs.

One limitation of our study was the use of a single urine measurement at each developmental stage to estimate EDC exposure given the short half-life of these biomarkers. Nevertheless, due to chronic and repetitive exposures, prior longitudinal assessments have suggested that relative EDC exposures over several months (to possibly a year) can be reasonably estimated based on a single-spot sample (51–54). Potential measurement error in exposure is compensated by our longitudinal assay of urinary phenol and phthalate biomarker concentrations. Puberty reflects a period of rapid physical and social change that may both influence exposure profile and modulate the impact of these compounds on developing mammary tissue. Another strength is the focus on Latina girls. A study of similarly aged U.S. girls showed differences in the urinary biomarker concentrations of phenols and phthalates by race/ethnicity (55). In addition to disparities in exposure profile, the U.S. cohort also reported an earlier age of thelarche among Hispanic girls compared with non-Hispanic white girls, indicating potential biological differences in breast development (56). The consequential drawback is that the findings of our study may not be generalizable to all race/ethnicities. Concentrations of BPA in this population were lower than similarly aged U.S. girls (57, 58), but only slightly lower than a cohort of girls in Mexico City (59). In contrast, concentrations of MEP were much higher in this cohort compared with U.S. girls (58), with a similar distribution detected in the Hispanic study (59). These discrepancies highlight potential differences in exposure profile between populations. Finally, we recommend cautious interpretation of the weaker pairwise comparisons of breast composition between tertiles of the many EDC biomarkers quantified. In our discussion of the results, we have chosen to highlight the stronger associations that are less likely due to chance. We encourage replication of these analyses in independent cohorts to validate these findings and to appraise population-specific sensitivities.

Higher estrogenic activity in childhood has previously been associated with early breast development in the GOCS cohort (60). Given these prior findings were independent of central activation or peripheral estrogen conversion associated with obesity, it was postulated that this estrogenic activity may reflect EDC action (60). This study suggests that the developing breast tissue of Latina girls is responsive to exogenous hormones during childhood and adolescence. Future studies would be useful to assess whether these shifts in pubertal breast density track through the life course to modify breast cancer risk.

No potential conflicts of interest were disclosed.

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC). Use of trade names is for identification only and does not imply endorsement by the CDC, the Public Health Service, or the U.S. Department of Health and Human Services.

Conception and design: A.M. Binder, C. Corvalan, K.B. Michels

Development of methodology: A.M. Binder, C. Corvalan, A. Pereira, K.B. Michels

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): C. Corvalan, A. Pereira, A.M. Calafat, J. Shepherd, K.B. Michels

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): A.M. Binder, A.M. Calafat, X. Ye, K.B. Michels

Writing, review, and/or revision of the manuscript: A.M. Binder, C. Corvalan, A. Pereira, A.M. Calafat, J. Shepherd, K.B. Michels

Study supervision: C. Corvalan, J. Shepherd, K.B. Michels

The authors wish to express their gratitude to Manori Silva, Ella Samandar, Jim Preau, Prabha Dwivedi, Xiaoliu Zhou, and Tao Jia, who performed the measurements of phthalates and phenols biomarkers.

This work was supported by Public Health Service grant R01CA158313 from the National Cancer Institute, NIH, U.S. Department of Health and Human Services (to K.B. Michels). This publication was also partially made possible by the Breast Cancer and the Environment Research Program (BCERP) award number U01ES026130 from the National Institute of Environmental Health Sciences, NIH (to K.B. Michels).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1.
McCormack
VA
,
dos Santos Silva
I
. 
Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis
.
Cancer Epidemiol Biomark Prev
2006
;
15
:
1159
69
.
2.
Boyd
NF
,
Guo
H
,
Martin
LJ
,
Sun
L
,
Stone
J
,
Fishell
E
, et al
Mammographic density and the risk and detection of breast cancer
.
N Engl J Med
2007
;
356
:
227
36
.
3.
Yaghjyan
L
,
Colditz
GA
,
Collins
LC
,
Schnitt
SJ
,
Rosner
B
,
Vachon
C
, et al
Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics
.
J Natl Cancer Inst
2011
;
103
:
1179
89
.
4.
Li
T
,
Sun
L
,
Miller
N
,
Nicklee
T
,
Woo
J
,
Hulse-Smith
L
, et al
The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer
.
Cancer Epidemiol Biomark Prev
2005
;
14
:
343
9
.
5.
Martin
LJ
,
Boyd
NF
. 
Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence
.
Breast Cancer Res
2008
;
10
:
201
.
6.
Samimi
G
,
Colditz
GA
,
Baer
HJ
,
Tamimi
RM
. 
Measures of energy balance and mammographic density in the Nurses’ Health Study
.
Breast Cancer Res Treat
2008
;
109
:
113
22
.
7.
Harris
HR
,
Tamimi
RM
,
Willett
WC
,
Hankinson
SE
,
Michels
KB
. 
Body size across the life course, mammographic density, and risk of breast cancer
.
Am J Epidemiol
2011
;
174
:
909
18
.
8.
Kusano
AS
,
Trichopoulos
D
,
Terry
KL
,
Chen
WY
,
Willett
WC
,
Michels
KB
. 
A prospective study of breast size and premenopausal breast cancer incidence
.
Int J Cancer
2006
;
118
:
2031
4
.
9.
Hsieh
CC
,
Trichopoulos
D
. 
Breast size, handedness and breast cancer risk
.
Eur J Cancer Oxf Engl 1990
1991
;
27
:
131
5
.
10.
Novotny
R
,
Daida
Y
,
Morimoto
Y
,
Shepherd
J
,
Maskarinec
G
. 
Puberty, body fat, and breast density in girls of several ethnic groups
.
Am J Hum Biol
2011
;
23
:
359
65
.
11.
Pike
MC
,
Krailo
MD
,
Henderson
BE
,
Casagrande
JT
,
Hoel
DG
. 
“Hormonal” risk factors, “breast tissue age” and the age-incidence of breast cancer
.
Nature
1983
;
303
:
767
70
.
12.
Colditz
GA
,
Frazier
AL
. 
Models of breast cancer show that risk is set by events of early life: prevention efforts must shift focus
.
Cancer Epidemiol Biomark Prev
1995
;
4
:
567
71
.
13.
Boyd
N
,
Martin
L
,
Chavez
S
,
Gunasekara
A
,
Salleh
A
,
Melnichouk
O
, et al
Breast-tissue composition and other risk factors for breast cancer in young women: a cross-sectional study
.
Lancet Oncol
2009
;
10
:
569
80
.
14.
Biro
FM
,
Pinney
SM
,
Huang
B
,
Baker
ER
,
Walt Chandler
D
,
Dorn
LD
. 
Hormone changes in peripubertal girls
.
J Clin Endocrinol Metab
2014
;
99
:
3829
35
.
15.
Diamanti-Kandarakis
E
,
Bourguignon
J-P
,
Giudice
LC
,
Hauser
R
,
Prins
GS
,
Soto
AM
, et al
Endocrine-disrupting chemicals: an endocrine society scientific statement
.
Endocr Rev
2009
;
30
:
293
342
.
16.
Hauser
R
,
Calafat
AM
. 
Phthalates and human health
.
Occup Environ Med
2005
;
62
:
806
18
.
17.
Philippat
C
,
Mortamais
M
,
Chevrier
C
,
Petit
C
,
Calafat
AM
,
Ye
X
, et al
Exposure to phthalates and phenols during pregnancy and offspring size at birth
.
Environ Health Perspect
2012
;
120
:
464
70
.
18.
Meeker
JD
. 
Exposure to environmental endocrine disruptors and child development
.
Arch Pediatr Adolesc Med
2012
;
166
:
952
8
.
19.
Wolff
MS
,
Teitelbaum
SL
,
McGovern
K
,
Windham
GC
,
Pinney
SM
,
Galvez
M
, et al
Phthalate exposure and pubertal development in a longitudinal study of US girls
.
Hum Reprod Oxf Engl
2014
;
29
:
1558
66
.
20.
Wolff
MS
,
Teitelbaum
SL
,
McGovern
K
,
Pinney
SM
,
Windham
GC
,
Galvez
M
, et al
Environmental phenols and pubertal development in girls
.
Environ Int
2015
;
84
:
174
80
.
21.
López-Carrillo
L
,
Hernández-Ramírez
RU
,
Calafat
AM
,
Torres-Sánchez
L
,
Galván-Portillo
M
,
Needham
LL
, et al
Exposure to phthalates and breast cancer risk in Northern Mexico
.
Environ Health Perspect
2010
;
118
:
539
44
.
22.
Shepherd
JA
,
Malkov
S
,
Fan
B
,
Laidevant
A
,
Novotny
R
,
Maskarinec
G
. 
Breast density assessment in adolescent girls using dual-energy X-ray absorptiometry: a feasibility study
.
Cancer Epidemiol Biomark Prev
2008
;
17
:
1709
13
.
23.
Tanner
J
. 
Growth at adolescense
.
Oxford
:
Blackwell Scientific Publications
; 
1962
.
24.
Shepherd
JA
,
Herve
L
,
Landau
J
,
Fan
B
,
Kerlikowske
K
,
Cummings
SR
. 
Clinical comparison of a novel breast DXA technique to mammographic density
.
Med Phys
2006
;
33
:
1490
8
.
25.
Weaver
CM
,
McCabe
LD
,
McCabe
GP
,
Novotny
R
,
Van Loan
M
,
Going
S
, et al
Bone mineral and predictors of bone mass in white, Hispanic, and Asian early pubertal girls
.
Calcif Tissue Int
2007
;
81
:
352
63
.
26.
Shepherd
JA
,
Kerlikowske
KM
,
Smith-Bindman
R
,
Genant
HK
,
Cummings
SR
. 
Measurement of breast density with dual X-ray absorptiometry: feasibility
.
Radiology
2002
;
223
:
554
7
.
27.
Samandar
E
,
Silva
MJ
,
Reidy
JA
,
Needham
LL
,
Calafat
AM
. 
Temporal stability of eight phthalate metabolites and their glucuronide conjugates in human urine
.
Environ Res
2009
;
109
:
641
6
.
28.
Ye
X
,
Bishop
AM
,
Reidy
JA
,
Needham
LL
,
Calafat
AM
. 
Temporal stability of the conjugated species of bisphenol A, parabens, and other environmental phenols in human urine
.
J Expo Sci Environ Epidemiol
2007
;
17
:
567
72
.
29.
Ye
X
,
Kuklenyik
Z
,
Needham
LL
,
Calafat
AM
. 
Automated on-line column-switching HPLC-MS/MS method with peak focusing for the determination of nine environmental phenols in urine
.
Anal Chem
2005
;
77
:
5407
13
.
30.
Silva
MJ
,
Samandar
E
,
Preau
JL
,
Reidy
JA
,
Needham
LL
,
Calafat
AM
. 
Quantification of 22 phthalate metabolites in human urine
.
J Chromatogr B Analyt Technol Biomed Life Sci
2007
;
860
:
106
12
.
31.
Boeniger
MF
,
Lowry
LK
,
Rosenberg
J
. 
Interpretation of urine results used to assess chemical exposure with emphasis on creatinine adjustments: a review
.
Am Ind Hyg Assoc J
1993
;
54
:
615
27
.
32.
Teass
AW
,
Biagini
RE
,
DeBord
G
,
Hull
RD
.
Application of biological monitoring methods. NIOSH Manual of Analytical Methods
.
Cincinnati (OH): National Institute for Occupational Safety and Health Division of Physical Sciences and Engineering
; 
1998
.
33.
Sánchez
BN
,
Hu
H
,
Litman
HJ
,
Téllez-Rojo
MM
. 
Statistical methods to study timing of vulnerability with sparsely sampled data on environmental toxicants
.
Environ Health Perspect
2011
;
119
:
409
15
.
34.
Chen
Y-H
,
Ferguson
KK
,
Meeker
JD
,
McElrath
TF
,
Mukherjee
B
. 
Statistical methods for modeling repeated measures of maternal environmental exposure biomarkers during pregnancy in association with preterm birth
.
Environ Health Glob Access Sci Source
2015
;
14
:
9
.
35.
Tyrrell
J
,
Melzer
D
,
Henley
W
,
Galloway
TS
,
Osborne
NJ
. 
Associations between socioeconomic status and environmental toxicant concentrations in adults in the USA: NHANES 2001-2010
.
Environ Int
2013
;
59
:
328
35
.
36.
Kobrosly
RW
,
Parlett
LE
,
Stahlhut
RW
,
Barrett
ES
,
Swan
SH
. 
Socioeconomic factors and phthalate metabolite concentrations among United States women of reproductive age
.
Environ Res
2012
;
115
:
11
7
.
37.
Tehranifar
P
,
Cohn
BA
,
Flom
JD
,
Protacio
A
,
Cirillo
P
,
Lumey
LH
, et al
Early life socioeconomic environment and mammographic breast density
.
BMC Cancer
2017
;
17
:
41
.
38.
Akinyemiju
TF
,
Tehranifar
P
,
Flom
JD
,
Liao
Y
,
Wei
Y
,
Terry
MB
. 
Early life growth, socioeconomic status, and mammographic breast density in an urban US birth cohort
.
Ann Epidemiol
2016
;
26
:
540
545.e2
.
39.
Wickham
H
.
ggplot2: elegant graphics for data analysis
.
New York
:
Springer-Verlag
; 
2009
.
40.
Binder
AM
,
Corvalan
C
,
Calafat
AM
,
Ye
X
,
Mericq
V
,
Pereira
A
, et al
Childhood and adolescent phenol and phthalate exposure and the age of menarche in Latina girls
.
Environ Health Glob Access Sci Source
2018
;
17
:
32
.
41.
Hong
E-J
,
Ji
Y-K
,
Choi
K-C
,
Manabe
N
,
Jeung
E-B
. 
Conflict of estrogenic activity by various phthalates between in vitro and in vivo models related to the expression of Calbindin-D9k
.
J Reprod Dev
2005
;
51
:
253
63
.
42.
Kumar
N
,
Sharan
S
,
Srivastava
S
,
Roy
P
. 
Assessment of estrogenic potential of diethyl phthalate in female reproductive system involving both genomic and non-genomic actions
.
Reprod Toxicol Elmsford N
2014
;
49
:
12
26
.
43.
Harris
CA
,
Henttu
P
,
Parker
MG
,
Sumpter
JP
. 
The estrogenic activity of phthalate esters in vitro
.
Environ Health Perspect
1997
;
105
:
802
11
.
44.
Lagarde
F
,
Beausoleil
C
,
Belcher
SM
,
Belzunces
LP
,
Emond
C
,
Guerbet
M
, et al
Non-monotonic dose-response relationships and endocrine disruptors: a qualitative method of assessment
.
Environ Health
2015
;
14
:
13
.
45.
Koniecki
D
,
Wang
R
,
Moody
RP
,
Zhu
J
. 
Phthalates in cosmetic and personal care products: concentrations and possible dermal exposure
.
Environ Res
2011
;
111
:
329
36
.
46.
Harley
KG
,
Kogut
K
,
Madrigal
DS
,
Cardenas
M
,
Vera
IA
,
Meza-Alfaro
G
, et al
Reducing phthalate, paraben, and phenol exposure from personal care products in adolescent girls: findings from the HERMOSA Intervention Study
.
Environ Health Perspect
2016
;
124
:
1600
7
.
47.
Dorgan
JF
,
Klifa
C
,
Deshmukh
S
,
Egleston
BL
,
Shepherd
JA
,
Kwiterovich
PO
, et al
Menstrual and reproductive characteristics and breast density in young women
.
Cancer Causes Control
2013
;
24
:
1973
83
.
48.
Jung
S
,
Egleston
BL
,
Chandler
DW
,
Van Horn
L
,
Hylton
NM
,
Klifa
CC
, et al
Adolescent endogenous sex hormones and breast density in early adulthood
.
Breast Cancer Res BCR
2015
;
17
:
77
.
49.
Mouritsen
A
,
Frederiksen
H
,
Sørensen
K
,
Aksglaede
L
,
Hagen
C
,
Skakkebaek
NE
, et al
Urinary phthalates from 168 girls and boys measured twice a year during a 5-year period: associations with adrenal androgen levels and puberty
.
J Clin Endocrinol Metab
2013
;
98
:
3755
64
.
50.
Sprague
BL
,
Trentham-Dietz
A
,
Hedman
CJ
,
Wang
J
,
Hemming
JD
,
Hampton
JM
, et al
Circulating serum xenoestrogens and mammographic breast density
.
Breast Cancer Res
2013
;
15
:
R45
.
51.
Calafat
AM
,
Longnecker
MP
,
Koch
HM
,
Swan
SH
,
Hauser
R
,
Goldman
LR
, et al
Optimal exposure biomarkers for nonpersistent chemicals in environmental epidemiology
.
Environ Health Perspect
2015
;
123
:
A166
168
.
52.
Johns
LE
,
Cooper
GS
,
Galizia
A
,
Meeker
JD
. 
Exposure assessment issues in epidemiology studies of phthalates
.
Environ Int
2015
;
85
:
27
39
.
53.
Teitelbaum
SL
,
Britton
JA
,
Calafat
AM
,
Ye
X
,
Silva
MJ
,
Reidy
JA
, et al
Temporal variability in urinary concentrations of phthalate metabolites, phytoestrogens and phenols among minority children in the United States
.
Environ Res
2008
;
106
:
257
69
.
54.
Engel
LS
,
Buckley
JP
,
Yang
G
,
Liao
LM
,
Satagopan
J
,
Calafat
AM
, et al
Predictors and variability of repeat measurements of urinary phenols and parabens in a cohort of Shanghai women and men
.
Environ Health Perspect
2014
;
122
:
733
40
.
55.
Wolff
MS
,
Teitelbaum
SL
,
Pinney
SM
,
Windham
G
,
Liao
L
,
Biro
F
, et al
Investigation of relationships between urinary biomarkers of phytoestrogens, phthalates, and phenols and pubertal stages in girls
.
Environ Health Perspect
2010
;
118
:
1039
46
.
56.
Biro
FM
,
Greenspan
LC
,
Galvez
MP
,
Pinney
SM
,
Teitelbaum
S
,
Windham
GC
, et al
Onset of breast development in a longitudinal cohort
.
Pediatrics
2013
;
132
:
1019
27
.
57.
Buttke
DE
,
Sircar
K
,
Martin
C
. 
Exposures to endocrine-disrupting chemicals and age of menarche in adolescent girls in NHANES (2003-2008)
.
Environ Health Perspect
2012
;
120
:
1613
8
.
58.
Wolff
MS
,
Pajak
A
,
Pinney
SM
,
Windham
GC
,
Galvez
M
,
Rybak
M
, et al
Associations of urinary phthalate and phenol biomarkers with menarche in a multiethnic cohort of young girls
.
Reprod Toxicol Elmsford N
2017
;
67
:
56
64
.
59.
Watkins
DJ
,
Téllez-Rojo
MM
,
Ferguson
KK
,
Lee
JM
,
Solano-Gonzalez
M
,
Blank-Goldenberg
C
, et al
In utero and peripubertal exposure to phthalates and BPA in relation to female sexual maturation
.
Environ Res
2014
;
134
:
233
41
.
60.
Pereira
A
,
Corvalán
C
,
Uauy
R
,
Klein
KO
,
Mericq
V
. 
Ultrasensitive estrogen levels at 7 years of age predict earlier thelarche: evidence from girls of the growth and obesity Chilean cohort
.
Eur J Endocrinol
2015
;
173
:
835
42
.